Why ARS Pharmaceuticals, Inc.’s (SPRY) Stock Is Down 5.15%
As of Friday, July 31, ARS Pharmaceuticals, Inc.’s SPRY share price has dipped by 5.15%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Commentary & Analysis
Why ARS Pharmaceuticals, Inc.’s (SPRY) Stock Is Down 6.14%
As of Monday, July 20, ARS Pharmaceuticals, Inc.’s SPRY share price has dipped by 6.14%, which has investors questioning if this is right time to buy.Michael Rose
Why ARS Pharmaceuticals, Inc.’s (SPRY) Stock Is Down 5.56%
As of Friday, July 17, ARS Pharmaceuticals, Inc.’s SPRY share price has dipped by 5.56%, which has investors questioning if this is right time to buy.Jenna Brashear
Why ARS Pharmaceuticals, Inc.’s (SPRY) Stock Is Up 7.23%
As of Friday, June 26, ARS Pharmaceuticals, Inc.’s SPRY share price has surged by 7.23%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why ARS Pharmaceuticals, Inc.’s (SPRY) Stock Is Down 26.94%
As of Thursday, June 25, ARS Pharmaceuticals, Inc.’s SPRY share price has dipped by 26.94%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | SPRY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $507.9 | $252.6 | 38% |
|
| Shares Out (Mil) | 99.3 | 52.3 | 62% |
|
| Institutional Ownership | 90.4% | 92.1% | 58% |
|
| Float (Mil) | 48.4 | 40.2 | 46% |
|
| Beta | 0.80 | 0.95 | 47% |
|
| Avg Daily Volume (000s) | 3,040 | 455 | 87% |
|
| Price Change (52-week) |
(71.4%) | 52.9% | 9% |
|
| Growth | SPRY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 36.5% | 13.6% | 92% |
|
| Net Income (5yr) | (174.5%) | (9.9%) | 0% |
|
| EPS (5yr) | (101.0%) | 16.0% | 1 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.5%) | (15.6%) | 43% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($0.493) | ($1.720) | ($0.943) | |
| Month Ago EPS | ($0.493) | ($1.700) | ($0.853) | |
| # Rev Up | 0 | 0 | 2 | |
| # Rev Down | 1 | 1 | 0 | |
| Three Months Ago EPS | ($0.430) | ($1.568) | ($0.758) | |
| Year/Year Chg | (19.2%) | (1.1%) | (68.7%) | |
| Financials | SPRY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $99 | $38 | 27% |
|
| Net Income (TTM) (Mil) | ($198) | ($43) | 7% |
|
| EPS (TTM) | ($2.002) | ($1.600) | 15% |
|
| Operating Cash Flow (TTM) (Mil) | ($175) | ($31) | 4% |
|
| Net Cash Flow (TTM) (Mil) | ($16) | $5 | 28% |
|
| Long-Term Debt (Q1) (Mil) | $171 | $5 | 49% |
|
| Enterprise Value (Q1) (Mil) | $708 | $180 | 38% |
|
| Valuation | SPRY | Industry Median |
Percentile (All Stocks) |
|
| P/B | 8.25 | 2.56 | 87% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | SPRY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 59.4% | 63.8% | 72% |
|
| Net Margin | (200.0%) | (67.3%) | 5% |
|
| ROA | (64.4%) | (49.8%) | 9% |
|
| ROE | (136.4%) | (55.5%) | 7% |
|
| Liabilities to Assets | 78.7% | 30.3% | 74% |
|
| F-Score | 1 | 3 | na |
|
ARS Pharmaceuticals, Inc. did not pass any screens on 7/31/2026.
